Articles tagged "Lung transplantation"

2019 American Transplant Congress
Caregiving in Thoracic Transplantation–A SR/MA
A. A. Rmilah, J. Lau, R. Mendpara, P. Erwin, C. C. Kennedy
Mayo Clinic, Rochester, MN
*Purpose: Caregivers are required for heart and lung transplantation, however, little emphasis is placed on the pre-transplant caregiving experience. Our objective was to perform a…
2019 American Transplant Congress
Bronchoalveolar Lavage Biomarkers Predict Lung Transplant Survival
A. Zarinsefat¹, J. Y. Yang², R. Sarwal¹, J. Liberto¹, D. Watson³, S. Verleden⁴, M. Sarwal¹
¹UC San Francisco, San Francisco, CA, ²Johns Hopkin, Baltimore, MD, ³Kit Bio, Los Altos, CA, ⁴KU Leuven, Leuven, Belgium
*Purpose: In lung transplants (LTx), chronic rejection remains a major cause of morbidity and mortality following transplantation, mainly from chronic lung allograft dysfunction (CLAD). Two…
2019 American Transplant Congress
Syphilis Transmission in Solid Organ Transplantation
M. Morrison, M. Hurtik, G. M. Lyon, S. Pouch
Emory University Hospital, Atlanta, GA
*Purpose: Syphilis is a sexually transmitted infection that affects people worldwide. While transmission generally occurs via sexual contact, other modes of transmission are possible, including…
2019 American Transplant Congress
Azole Use and Fungal Pathogens in Cystic Fibrosis versus Non-Cystic Fibrosis Lung Transplant Recipients
F. J. Marco Canosa¹, K. Brizendine², H. Hassouna³
¹Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, ²Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ³Infectious Disease, Spectrum Health Infectious Disease, Grand Rapids, MI
*Purpose: Cystic fibrosis (CF) patients exhibit unique pharmacokinetic principles. Azole antifungals show marked inter- and intra-patient variability. We aimed to improve itraconazole (ITR) use and…
2019 American Transplant Congress
Not All Donor-Specific Antibodies Are Equal: Predictors of Risk of Chronic Lung Allograft Dysfunction
C. J. Iasella¹, C. R. Ensor², M. Marrari³, M. Mangiola³, C. A. Moore¹, M. R. Morrell⁴, J. Pilewski⁴, J. F. McDyer⁴, A. Zeevi³
¹Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Florida Hospital Transplant Institute, AdventHealth Orlando, Orlando, FL, ³Pathology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA
*Purpose: Donor-specific HLA antibodies (DSA) have been previously associated with chronic lung allograft dysfunction (CLAD). However, the DSA characteristics that predict risk of CLAD are…
2019 American Transplant Congress
Impact of Multidrug-Resistant Microbes of Donor Lower Respiratory Tract on Early Posttransplant Pneumonia in Bilateral Lung Transplant Recipients without Pretransplant Infection
S. HAN¹, S. Kim², M. Park³, J. Lee⁴, H. Paik⁴
¹Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Internal Medicine, Yonsei University Health SystemYonsei University Health System, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of, ³Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of, ⁴Chest Surgery, Yonsei University Health System, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of
*Purpose: Colonized microbes in lower respiratory tract (LRT) of deceased donor allograft can potentially cause early posttransplant pneumonia (EPTP) that leads to detrimental outcome in…
2019 American Transplant Congress
Effect of Enoxaparin Prophylaxis on Early VTE Post Lung Transplant
S. Marshall¹, K. Tsveybel¹, S. Boukedes¹, P. Burkett², R. Chepuri², A. Coppolino³, M. Divo², S. El-Chemaly², S. Keller², J. Kennedy², H. Mallidi³, G. Mody³, T. Thaniyavarn², A. Trindade², K. Townsend¹, H. Goldberg²
¹Lung Transplant, Brigham & Women's Hospital, Boston, MA, ²Pulmonary Division, Brigham & Women's Hospital, Boston, MA, ³Thoracic Surgery, Brigham & Women's Hospital, Boston, MA
*Purpose: Thromboembolic complications are common post-transplant leading to significant morbidity. We instituted early enoxaparin prophylaxis (ppx) in lung transplant recipients (LTR) due to an observed…
2019 American Transplant Congress
Decline in Club Cell Secretory Protein Results in Immune Responses to Lung Self-Antigens (Kα1 Tubulin and Collagen V) and Development of Chronic Rejection Following Human Lung Transplantation
Y. Itabashi¹, R. Ravichandran¹, M. Sharma¹, R. Hachem², R. Bremner¹, M. Smith¹, T. Mohanakumar¹
¹Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, ²Washington University School of Medicine, St. Louis, MO
*Purpose: Club cell secretory protein (CCSP) levels have been employed as a biomarker for respiratory stress in athletes, asthma patients, and in experimental acute and…
2019 American Transplant Congress
Target Itraconazole Trough Concentration for Prophylaxis in Lung Transplant
J. A. Morillas-Rodriguez¹, H. Hassouna², F. Marco-Canosa³, K. D. Brizendine¹
¹Infectious disease, Cleveland Clinic, Cleveland, OH, ²Infectious disease, Spectrum health, Grand rapids, MI, ³Cleveland Clinic, Cleveland, OH
*Purpose: Itraconazole (ITR) therapeutic drug monitoring (TDM) for prophylaxis in lung transplant recipients (LTR) is not well characterized. Our purpose was to evaluate ITR trough…
2019 American Transplant Congress
Lung Transplantation in the Elderly Patients with Multi-Comorbidities
N. Shigemura, Y. Toyoda
Temple University Health System / Lewis Katz School of Medicine, Philadelphia, PA
*Purpose: Recently there is an outstanding steadily increase in elderly patients above 70 years old who are referred to our center as potential candidates for…